Cochrane UK



Beta-blocker use in acute myocardial infarction – a Cochrane systematic review which affirms routine clinical practiceReferencesADDIN Mendeley Bibliography CSL_BIBLIOGRAPHY 1.Safi, S. et al. Beta-blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database Syst. Rev. (2019). doi:10.1002/14651858.CD0124842.Washburn, M. F. & Cannon, W. B. Bodily Changes in Pain, Hunger, Fear, and Rage. J. Philos. Psychol. Sci. Methods (1917). doi:10.2307/20136243.Brodde, O. E. & Michel, M. C. Adrenergic and muscarinic receptors in the human heart. Pharmacol. Rev. 51, 651–90 (1999).4.Ahlquist, R. P. A study of the adrenotropic receptors. Am. J. Physiol. 153, 586–600 (1948).5.Black, J. W., Crowther, A. F., Shanks, R. G., Smith, L. H. & Dornhorst, A. C. A new adrenergic beta-receptor antagonist. Lancet 1, 1080–1 (1964).6.Quirke, V. Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958-1978. Med. Hist. 50, 69–92 (2006).7.Zhu, W., Woo, A. Y. H., Zhang, Y., Cao, C. M. & Xiao, R. P. β-Adrenergic Receptor Subtype Signaling in the Heart: From Bench to the Bedside. Curr. Top. Membr. 67, 191–204 (2011).8.Moniotte, S. et al. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103, 1649–55 (2001).9.Bristow, M. R. et al. β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circ. Res. 59, 297–309 (1986).10.Ibanez, B. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 39, 119–77 (2018).11.Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial Infarction. N. Engl. J. Med. 304, 801–7 (1981).12.Friedman, L. M. A Randomized Trial of Propranolol in Patients With Acute Myocardial Infarction: I. Mortality Results. JAMA J. Am. Med. Assoc. 247, 1707–14 (1982).13.First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2, 57–66 (1986).14.Roffi, M. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. (2016). doi:10.1093/eurheartj/ehv32015.O’Gara, P. et al. ACCF/AHA guideline for the management of ST-elevation myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 61, 78–140 (2013).16.Yang, E. H., Brilakis, E. S., Reeder, G. S. & Gersh, B. J. Modern Management of Acute Myocardial Infarction. Curr. Probl. Cardiol. 31, 769–817 (2006).17.Kontos, M. C. et al. Treatment and outcomes in patients with myocardial infarction treated with acute β-blocker therapy: Results from the American College of Cardiology’s NCDR?. Am. Heart J. 161, 864–70 (2011). ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download